Welcome to the ALK Patient Gateway Newsletter for January 2023.
Our understanding of the molecular causes of lung cancer continues to move forward, driving growing numbers of targeted treatments. When it comes to ALK-positive NSCLC, researchers are working to develop targeted drugs for some of the rarer ALK fusions.
Take a look below at recent research news in ALK-positive lung cancer and non-small cell lung cancer (NSCLC). And don’t forget to check out the useful resources for ALK-positive lung cancer survivors and their caregivers!
Research News
Targeted Oncology
Targeted Therapy, Immunotherapy Propel 10 Years of Progress in NSCLC
Published Dec 1, 2022
NewsBeezer
Targeted therapies and expanded access to NGS improve lung cancer decision-making
Published Nov 3, 2022
Targeted Oncology
Greater Understanding of the Biology of NSCLC Propels Treatment Options Forward
Published Oct 17, 2022
MDPI
Therapeutic Advances of Rare ALK Fusions in Non-Small Cell Lung Cancer
Published Oct 16, 2022
MDPI
Biomarker-Targeted Therapies in Non–Small Cell Lung Cancer: Current Status and Perspectives
Published Oct 12, 2022
Resources for ALK Survivors & Caregivers
- Get the Answers You Need
- Caregiver Starter Kit: 5 Resources
- Benefits of Palliative Care for People Living with Lung Cancer
If you need further assistance, please email us at support@lungevity.org. Our team is always here to assist you.
